Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years old;~* Diagnosed primary ITP for at least 12 months;~* Had received at least one first-line ITP treatment with no response or recurrence after treatment;~* Had a platelet count \<30×10\^9/L within 48 hours before the first dose;~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;~* Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form.~Exclusion Criteria:~* Had a history of bone marrow stem cell abnormalities or myelodysplastic syndrome other than ITP-specific changes.~* Had arterial thrombosis, or venous thromboembolism; severe cardiovascular diseases; malignant tumors; secondary thrombocytopenia caused by autoimmune diseases.~* Underwent splenectomy within 12 weeks before the first dose;~* Had received ITP treatments (including rescue treatment) within 2 weeks before the first dose;~* Had received romiplostim (Nplate®) or eltrombopag (Revolade®), rhTPO or other agents that stimulate TPO receptors (also known as c-Mpl), and hematopoietic growth factors (HGFs) within 4 weeks before the first dose;~* Had received antineoplastic agents within 8 weeks before the first administration, but when treating ITP with hypomethylating agents (HMA) such as decitabine, a 4-week washout period was acceptable, as judged by the investigator;~* Had received antibody-based therapies within 14 weeks before the first dose; 8) had serum creatinine or total bilirubin \>1.5 upper limit of normal (ULN), alanine transaminase (ALT) or aspartate transaminase (AST) \>3 ULN, hemoglobin \< 100g/L, absolute neutrophil count \<1.5x10\^9/L;~* Had prothrombin time (PT) or prothrombin time-international normalized ratio (PT-INR) or activated partial thromboplastin time (APTT) exceeded 20% of the reference range of normal values.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QL0911 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).